BackSAB Biotherapeutics Overview

SAB Biotherapeutics Current Assets

SAB Biotherapeutics's current assets is $110M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$112.78M
↑ 592.05% YoYΔ $96.49M vs prior year quarter

Peer average

Loading

SAB Biotherapeutics Current Assets History

Loading

SAB Biotherapeutics vs. peers: Current Assets Comparison

Loading

SAB Biotherapeutics Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics (SABS) FAQ

As of the most recent data (March 2026), SABS shows a current assets of $110M. That compares with $16M in the prior-year period — up 592.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SABS's current assets is now $110M (was $16M) — a 592.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics is outperforming or lagging.

Tracking SABS's current assets over time shows whether SAB Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $16M in the prior-year period — up 592.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has SAB Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $110M) with ownership activity and broader fundamentals.